HPV 16+ Cancer Pipeline Analysis: Insights into Emerging Therapies, Key Companies, Clinical Trials and Future Pipeline Outlook | DelveInsight

(MENAFN- GlobeNewsWire - Nasdaq) Los Angeles, USA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HPV 16+ Cancer Pipeline Analysis: Insights into Emerging Therapies, Key Companies, Clinical Trials and Future Pipeline Outlook | DelveInsight

HPV 16+ Cancer Pipeline is in its nascent stage and is developing with a more targeted therapeutic approach combined with other approved treatments.

DelveInsight's ' HPV 16+ Cancer Pipeline Insights ' report offers comprehensive coverage of the emerging HPV 16+ Cancer therapeutics outlook in different stages of clinical and pre-clinical development along with dormant, inactive and abandoned drugs agents. 

The HPV 16+ Cancer Pipeline report provides a holistic picture of the ongoing clinical trials, partnerships and recent happenings in the domain and growth prospects across the HPV 16+ Cancer space.

Some of the key highlights from the HPV 16+ Cancer Pipeline report:

• The HPV 16+ Cancer Pipeline report offers a rich analysis of 14+ key players and 14+ key therapies.
• HPV 16+ Cancer pipeline comprises emerging therapies in different stages of the clinical phase such as include VGX-3100, ISA101b, PDS0101, VB10.16, BNT113, ADXS11–001, CUE 101, HB-201, HB-202, PRGN-2009, TG 4001, KITE-439, and others.
• Some of the key companies working to strengthen the HPV 16+ Cancer Pipeline are PDS Biotechnology, ISA Pharmaceuticals/Regeneron Pharmaceuticals, Inovio Pharmaceuticals, BioNTech, Transgene, Advaxis, Cue Biopharma, Hookipa Biotech, Precigen, Kite Pharma, among others
• In March 2021, Transgene announced the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT03260023).
• In December 2020, HOOKIPA Pharma announced positive interim Phase I data on HB-201, its replicating monotherapy for the treatment of HPV16+ cancers. The results were from the initial dose-escalation cohorts of an ongoing Phase I/II clinical trial (NCT04180215) evaluating HB- 201 as therapy for patients with advanced HPV16+ metastatic cancers.

Request for Report Sample to know more about the therapies set to grab maximum patient pool @ HPV 16+ Cancer Emerging Therapies and Forecast

Human papillomaviruses (HPVs) are a group of viruses behind the global burden of sexually transmitted infections. With over 100 types of viruses known to date, there are at least 14 that are cImmunostimulantsonsidered as high-risk cancer-causing forms leading to cervical, head and neck, vulvar, oropharyngeal, penile, anal, and other forms of cancer.

For more information on emerging drugs, visit HPV 16+ Cancer Pipeline Analysis

HPV 16+ Cancer Pipeline Drugs Immunostimulants

Drug Company Phase MoA RoA GX 188E GenexinePhase IIImmunostimulantsIntramuscular VGX-3100 Inovio PharmaceuticalsPhase IIIGene transferenceIntramuscular ISA101b ISA Pharmaceuticals/Regeneron PharmaceuticalsPhase IIImmunostimulantsSubcutaneous PDS0101 PDS BiotechnologyPhase IIImmunostimulantsSubcutaneous BNT113 BioNTechPhase IIImmunostimulantsIntravenous VB10.16 Vaccibody AS/RochePhase IIAntigen-presenting cell modulatorsIntramuscular ADXS11–001 AdvaxisPhase IIIGene transferenceIntravenous CUE 101 Cue BiopharmaPhase IInterleukin-2 replacementsIntravenous PRGN-2009 PrecigenPhase IIImmunostimulantsSubcutaneous HB-202 Hookipa BiotechPhase I/IIImmunostimulantsIntravenous HB-201 Hookipa BiotechPhase I/IIImmunostimulantsIntravenous TG 4001 TransgenePhase IIImmunostimulantsSubcutaneous KITE-439 Kite PharmaPhase IT lymphocyte replacementsNA

Request for Sample to know more @ HPV 16+ Cancer Pipeline Analysis, Key Companies, and Futuristic Trends

HPV 16+ Cancer Therapeutic Assessment

The HPV 16+ Cancer Pipeline report lays down complete insights into active HPV 16+ Cancer pipeline therapies segmented by Stage, Product Type, Route of Administration, Type of Molecule, Target, and Mechanism of Action.

By Product Type

• Mono
• Combination

By Stage

• Discovery
• Pre-clinical
• IND
• Phase I
• Phase II
• Phase III
• Pre-registration

By Molecule Type

• Monoclonal Antibody
• Peptides
• Vaccines
• Small molecule

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical

By Mechanism of Action

• Gene transference
• Interleukin-2 replacements
• Immunostimulants
• Antigen-presenting cell modulators
• T lymphocyte replacements

By Targets

• Antigen-presenting cell
• HPV16 protein

Discover more about recent healthcare trends and pipeline activities for Informative Business Decisions, Licensing Services and Consulting Solutions

Scope of the Report

Coverage : Global
Key Players : PDS Biotechnology Corp. /Merck, ISA Pharmaceuticals/Regeneron Pharmaceuticals, Inovio Pharmaceuticals, Transgene, Advaxis, Cue Biopharma, Hookipa Biotech, Precigen, Transgene, Kite Pharma, and others. 
Key HPV 16+ Cancer Pipeline Therapies : VGX-3100, ISA101b, PDS0101, VB10.16, BNT113, ADXS11–001, CUE 101, TG 4001, KITE-439, HB-201, HB-202, PRGN-2009, and others. 

Reach out @ HPV 16+ Cancer Pipeline: Novel therapies and Emerging technologies

Table of Contents

1 Report Introduction 2 HPV 16+ Cancer Disease Overview 3 HPV 16+ Cancer Pipeline Outlook 4 Comparative Analysis 5 HPV 16+ Cancer Therapeutic Products in Clinical Stage 6 HPV 16+ Cancer Therapeutic Products in Non-clinical Stage 7 HPV 16+ Cancer Therapeutics Pipeline Analysis 8 Inactive HPV 16+ Cancer Pipeline Products 9 Appendix 10 Report Methodology 11 Consulting Services 12 Disclaimer 13 About DelveInsight

Visit to know more of what's covered @ HPV 16+ Cancer Emerging Therapies, Treatments and Ongoing Clinical Trials

Related Reports

Acute Bacterial Skin And Skin Structure Infections Market
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections - Market Insights, Epidemiology, and Market Forecast-2030" report .

Adeno Associated Virus Vectors In Gene Therapy Market
DelveInsight's "Adeno-Associated Virus Vectors in Gene Therapy - Market Insights, Epidemiology, and Market Forecast-2030" report.

Human Immunodeficiency Virus Type 1 Market
DelveInsight's "Human Immunodeficiency Virus Type-1 (HIV-1)- Market Insights, Epidemiology, and Market Forecast-2030" report. 
Bacterial Meningitis Market
DelveInsight's "Bacterial Meningitis Market Insights, Epidemiology, and Market Forecast-2030" report .

Browse through blog posts

Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market
COVID-19 Vaccine Landscape

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .

For more insights, visit Pharma, Healthcare, and Biotech News

Contact Us

Shruti Thakur 

+1(919)321-6187 

Tags HPV 16+ Cancer Pipeline HPV 16+ Cancer HPV 16+ Cancer Drug Pipeline HPV 16+ Cancer Treatments HPV 16+ Cancer Therapies Related Links

• Cervical Cancer Market
• PD-1 Resistant Head and Neck Cancer Market
• Advanced Liver Cancer Market
• Advanced Recurrent Ovarian Cancer Market

MENAFN07092021004107003653ID1102757876